Background: It is still undefined whether serum uric acid (SUA) is an independent risk factor for target organ damage (TOD) and cardiovascular events in human hypertension. We sought to investigate the association of SUA with subclinical cardiac, vascular, and renal alterations in never-treated uncomplicated essential hypertensives.
I
t is still debated whether serum uric acid (SUA) is an independent predictor of cardiovascular events or an indirect marker of adverse prognosis in the general population as well as in clinical conditions characterized by a high prevalence of hyperuricemia such as coronary or peripheral artery disease, hypertension, diabetes, and obesity.
In the past 5 decades the relationship between SUA levels and cardiovascular disease has been investigated in more than 40 epidemiologic and clinical studies involving up to 150,000 subjects. 1, 2 Large prospective studies have shown that SUA is an independent risk factor for cardiovascular events in the general, 3, 4 as well as in the hypertensive population. 5, 6 Other studies, however, have not confirmed a causal relationship between SUA and cardiovascular disease, concluding that SUA is merely associated with multiple risk factors, including hypertension, metabolic syndrome, diabetes, renal disease, and diuretic treatment. 7, 8 Finally, the association between SUA and cardiovascular events appears to be stronger in women than in men 9, 10 and in black individuals than in whites.
in US and British, 12, 13 and international hypertension guidelines. 14, 15 Only the European Society of Hypertension-European Society of Cardiology (ESH/ESC) guidelines recommend SUA measurement as a routine laboratory investigation. 14 The role of SUA in the pathogenesis of essential hypertension and the development of target organ damage still remains under active investigation.
In this study, we examined the relationship between SUA levels and preclinical cardiac and extracardiac target organ damage (TOD) in a large sample of asymptomatic subjects with recently diagnosed grade 1 and 2 hypertension to evaluate the role of SUA in the development of early cardiovascular alterations.
Methods

Study Population
A total of 580 consecutive, white, never-treated hypertensive subjects referred to our hospital outpatient clinic were included in the study on the basis of their history, physical, and laboratory examinations. The subjects were characterized by: (1) grade 1 or 2 hypertension, ie, clinic systolic blood pressure (BP) values between 140 and 179 mm Hg or diastolic BP, 90 and 109 mm Hg, diagnosed in the previous 12 months and confirmed during two visits at the outpatient clinic; (2) no history or clinical evidence of congestive heart failure, myocardial infarction, cardiac valve disease, coronary bypass surgery or angioplasty, diabetes mellitus and renal insufficiency, and no treatment with urate-lowering medication (allopurinol and probenecid); (3) any condition preventing technically adequate ambulatory BP monitoring (ABPM) (eg, atrial fibrillation or other major arrhythmias); and (4) secondary hypertension. After an informed written consent had been obtained, all patients underwent the following procedures: (1) clinic BP measurement; (2) routine investigations (blood chemistry, urinalysis, and 12-lead electrocardiogram at rest); (3) 24-h urine collection for microalbuminuria; (4) two 24-h ABPMs at 1-to 4-week intervals; (5) an echocardiogram; and (6) a carotid ultrasonographic scan. The study protocol was approved by the Ethics Committee of one of the institutions involved.
The SUA was determined by the urikase-peroxidase method. Hyperuricemia was diagnosed according to sexspecific criteria (Ͼ7.0 mg/dL in men and 6.0 mg/dL in women).
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Blood Pressure Measurements
Clinic BP was measured at 2 different visits in the outpatient clinic using a mercury sphygmomanometer and taking the first and fifth phases of Korotkoff sounds to identify systolic and diastolic BP, respectively. Measurements started after the subjects had comfortably rested for 5 min in the sitting position. Three measurements were taken at 1-min interval, and the average was used to define clinic systolic and diastolic BP.
The ABPM for 2 periods of 24-h was carried out in the nondominant arm using a Spacelabs 90207 device (Spacelabs Inc., Richmond, WA). The device was set to obtain BP readings at 15-min intervals during the day (7:00 AM to 11:00 PM) and at 20-min intervals during the night (11:00 PM to 7:00 AM). Patients were instructed to attend to their daily activities and keep the arm still at the time of measurements. All subjects were asked to go to bed no later than 11:00 PM and to arise not before 7:00 AM. The recordings were analyzed to obtain 24-h, daytime, and nighttime average systolic and diastolic BP and heart rate. Nocturnal dipping was defined as a reduction in the average systolic and diastolic BP at night more than 10% compared with daytime values. Each subject was classified according to the consistency of the dipping or nondipping status in the first and second ABPM periods: dipper on both recordings, nondipper on both recordings, nonreproducible dipper, or nondipper status.
Echocardiography
Technical details have been reported previously. 17 In brief, M-mode, two-dimensional, and Doppler echocardiographic examinations were performed with commercially available instruments. Left-ventricular mass (LVM) was estimated from end-diastolic left ventricular internal diameter (LVIDd), interventricular septum, and posterior wall thickness (PWT) according to the formula by Devereux and Reickek 18 and normalized to body surface area (BSA) and height 2.7 . Relative wall thickness was calculated as (2 ϫ PWT) / LVIDd. Patterns of left-ventricular geometry were defined according to Ganau et al 19 as follows: LV concentric remodeling, when a normal left-ventricular mass index (LVMI) was combined with a relative wall thickness (RWT) Ͼ0.45; eccentric left-ventricular hypertrophy (LVH), when an increased LVMI was associated with an RWT Ͻ0.45; and concentric LVH, when LVH occurred with an RWT Ͼ0.45. LV filling was assessed by mitral flow with standard pulsed Doppler technique. The following parameters were considered: early diastolic peak flow velocity (E), late diastolic peak flow velocity (A), and their ratio (E/A).
Carotid Ultrasonography
Technical details have been reported previously. 17 In brief, images of the extracranial carotid artery walls (common, bifurcation, and internal carotid arteries) were obtained in several projections by high-resolution, linear array, 7.5-to 10.0-MHz probes. Plaques were sought in the near and far walls of the entire extracranial tree based on the presence of a focal wall thickening. Intima-media thickness (IMT) was measured in the posterior wall of both common carotid arteries 5, 10, 15, 20, and 25 mm caudally to the bifurcation. 20 To obtain a mean value of common carotid IMT, all five measurements were averaged. Carotid RWT was calculated as (2 ϫ IMT/Dd) where Dd is the value of the common carotid internal diameter (intima-intima distance at end diastole).
Microalbuminuria
The 24-h urinary concentration of albumin was measured using a commercially available radioimmunoassay kit (Sclavo SPA, Cinisello Balsamo, Milan, Italy). The detection limit of the method was 0.5 mg/L.
Definition of Target Organ Damage
Target organ damage was defined by the presence of microalbuminuria (urinary albumin excretion: 30 to 300 mg/24 h) or ultrasonographic evidence of LVH and vascular alterations. In particular, LVH was defined as LVMI equal to or higher than 51 g/m 2.7 in men and 47 g/m 2.7 in women. 21 The presence of at least one carotid atherosclerotic plaque or diffuse IMT was taken as evidence of vascular alterations. A plaque was defined as a focal thickening greater than 1.3 mm in any segment of carotid arteries. Diffuse IMT was diagnosed when the average common carotid wall thickness exceeded 0.8 mm.
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Statistical Analysis
Statistical analysis was performed by the SAS system (version 6.12; SAS Institute, Cary, NC). Values were expressed as mean Ϯ SD or as percentages. Serum uric acid levels were stratified according to tertiles in the entire study population and in each sex group. Means were compared by the Student's t-test for independent samples. Analysis of categorical data was carried out with the 2 test or Fisher's exact test when appropriate. Differences within groups were tested using analysis of variance (ANOVA). The strength of correlation between variables was tested by linear correlation analysis. To assess the independent contribution of several variables, including SUA, to TOD, a logistic regression analysis was performed by calculating the odds ratios and their 95% confidence limits. The limit of statistical significance was set at P Ͻ .05.
Results
The screening process involved 670 consecutive untreated patients with grades 1 and 2 hypertension. Of these, 21 were excluded because of secondary hypertension, 19 for type 2 diabetes mellitus, 15 for valvular disease, 8 due to unwillingness to participate or to miscellaneous reasons, and 3 under treatment with urate-lowering medication. Patients who reported a severely disturbed sleep due to ABPM procedure and those who disregarded the recommendations about the bed rest time were also excluded from the study (n ϭ 8). Thus, 596 hypertensive subjects met the inclusion criteria; 580 of them completed the study, having ABPM and ultrasonographic examinations of good technical quality. Mean age was 45 Ϯ 12 years, mean clinic BP was 145 Ϯ 12/95 Ϯ 7 mm Hg; sex distribution was 61% and 49% for men and women, respectively. As expected, SUA levels and the prevalence of hyperuricemia (12.5% v 2.5%, P Ͻ .0001) were significantly higher in men than in women. In men, a trend toward higher values of body mass index (BMI), serum creatinine, prevalence of ATP III-defined metabolic syndrome (MS), LVMI, carotid IMT, and urinary albumin excretion was also present. Tables 1 and 2 show demographic and clinical characteristics according to SUA tertiles and sex. The BMI, serum glucose, total cholesterol, triglycerides, and prevalence of MS showed a progressive increase in SUA tertiles in both sexes. This was not the case for other parameters, such as clinic BP, heart rate, ambulatory BP values, prevalence of nondipping pattern, HDL cholesterol, LVMI, and carotid IMT. An older age (P Ͻ .05) and greater values of urinary albumin excretion (P ϭ .05) were observed in women in the upper SUA tertile; no age-related differences were present in men.
Uric Acid Levels and Single or Multiple Organ Damage
The overall prevalence of LVH, carotid alterations, and microalbuminuria was 28.1%, 27.0%, and 7.6%, respectively. No difference in the prevalence of these TOD markers was present among SUA tertiles in the entire study population. Similar results were obtained for the prevalence rates of concentric and eccentric LVH, carotid thickening, and microalbuminuria in both sexes (Tables 1   and 2 ). A greater prevalence of carotid plaques was found in women in the upper SUA tertile compared with those in the lower one (25.0% v 14.9%, P Ͻ .05) and in men in the middle as compared with their counterpart in the lower tertile (24.7% v 13.7, P Ͻ .05) (Fig. 1 ). This trend, however, was weakened in both sexes after controlling for several variables in a logistic regression analysis (discussed later). Furthermore, when patients were categorized according to the presence or absence of TOD, that is, with or without LVH (4.9 Ϯ 1.4 v 4.9 Ϯ 1.4 mg/dL), carotid abnormalities (5.0 Ϯ 1.4 v 4.9 Ϯ 1.4 mg/dL), or microalbuminuria (4.9 Ϯ 1.4 v 4.9 Ϯ 1.4 mg/dL), no significant intergroup differences in SUA levels were found.
In a further analysis, patients were classified according to the number of organs involved. In those with multiple organ damage (two or three organs) SUA levels were significantly higher as compared with individuals with a single or no organ involvement (5.1 Ϯ 1.3 or 5.2 Ϯ 1.4 v 4.9 Ϯ 1.4 or 4.9 Ϯ 1.3 mg/dL, respectively, P Ͻ .05). The association of SUA with multiple TOD, however, was not confirmed after adjusting for several confounders in a multiple regression analysis.
Univariate Analyses
In the entire study population, SUA showed a direct association with BMI, serum creatinine, blood glucose, total and LDL cholesterol, triglycerides, LVM and LVMI, carotid IMT, and urinary albumin excretion. The SUA was also inversely related to HDL cholesterol. No association was present between SUA and age, clinic and ambulatory BP. When the analysis was repeated separately in each sex, the association between SUA and LVMI, carotid IMT, and urinary albumin excretion was no more significant (Table 3) .
Multivariate Analyses
The relation of variables such as age (Ͻ50 v Ͼ50 years), BMI (Ͻ25 v Ͼ25 kg/m 2 ), 48-h ambulatory systolic BP (Ͻ140 v Ͼ140 mm Hg), plasma glucose (Ͻ110 v Ͼ110 mg/dL), total cholesterol (Ͻ200 v Ͼ200 mg/dL), triglycerides (Ͻ170 v Ͼ170 mg/dL), HDL cholesterol (Ͻ40 v 40 mg/dL in men, Ͻ50 v Ͼ50 mg/dL in women), and smoking (no/yes), with a single or multiple TOD (2 or 3 markers), was analyzed by a logistic regression model with stepwise selection. In this model the relation of SUA with TOD was analyzed as each 1.1 mg/dL increase (ie, 1 SD), being the prevalence of hyperuricemia in our series relatively low. Table 4 shows that age, ambulatory BP, and BMI, but not SUA, were independent predictors of LVH, carotid atherosclerosis, microalbuminuria, and multiple TOD. Male sex was associated with both carotid atherosclerosis and multiple TOD, whereas smoking predicted multiple TOD.
Discussion
Our study in a large cohort of untreated subjects with recently diagnosed grade 1 and 2 hypertension provides several interesting findings. The SUA levels were significantly related to a variety of health-related factors, namely, BMI, serum levels of creatinine, glucose, and triglycerides but not with clinic and ambulatory BP. In the entire population SUA levels showed a direct significant association with validated markers of TOD, such as LVMI, carotid IMT, and urinary albumin excretion. This association, however, became negligible when this analysis was separately performed in each sex and, more importantly, after multivariate analyses. When the relationship between SUA and preclinical organ involvement was further investigated according to the presence or absence of LVH, carotid wall thickening/plaque, and mi- croalbuminuria, no significant differences in the prevalence of these TOD markers were found across the SUA tertiles in both sexes. Patients with multiple TOD had higher SUA levels than their counterparts with a single or no organ involvement. This difference, however, was no more statistically significant after adjusting for several confounders.
The following aspects of our findings deserve further comments. In our series, hyperuricemia was present at a lower percentage than previously reported in studies where increased SUA levels were found in one-third of untreated essential hypertensives, in 50% of subjects on antihypertensive treatment, and in up to 75% of patients with severe hypertension or renal dysfunction. 22 This is probably because our sample was characterized by a younger age, shorter duration of hypertension, lower BP values, and the absence of pathologic conditions with a high prevalence of hyperuricemia, such as diabetes, renal dysfunction, and cardiovascular complications.
A novel finding of our study, extending previous information simply based on clinic BP measurement, 23 is that SUA levels were unrelated to ambulatory BP values and to a reproducible nondipping pattern assessed by two ABPM recordings. This latter clinical trait is known to be associated with an increased risk of TOD and cardiovascular events. Thus, this observation does not support the possibility that SUA directly contributes to BP elevation in the early phases of uncomplicated hypertension or, alternatively, that it is a marker of an increased 24-h BP load, particularly at night.
Our results, obtained in a large, apparently healthy hypertensive population in the absence of confounding conditions such as diabetes, overt concomitant diseases, and antihypertensive therapy, confirm that SUA levels are strictly related with anthropometric variables such as BMI and BSA (which, in turn, influence cardiac dimensions and artery wall thickness) and with a clustering of well-documented metabolic risk factors.
Our most important observation is the lack of an independent association between SUA levels and TOD at cardiac, vascular, and renal level in hypertensive subjects. Our results are in accordance with previous studies either in the general population 24 or in the hypertensive population, 22 but are in contrast with other studies showing a significant positive relation between SUA and TOD in untreated and treated essential hypertensives. 23, 25, 26 Iribarren et al, 24 analyzing a biracial cohort of 11,488 middleaged men and women included in the Atherosclerosis Risk in Communities study, showed that SUA was unrelated to asymptomatic carotid atherosclerosis as assessed by high resolution ultrasound imaging at three levels of the carotid artery tree. Campo et al 22 found that hyperuricemia was not an independent marker of LVH, grades 1-2 retinopathy, and proteinuria in a study sample of 677 male hypertensives. However, it predicted the presence of these damages in the group with a low urate renal excretion, suggesting that hyperuricemia may be an indicator of TOD in urate underexcreting patients. Tsioufis et al, 25 assessing the relationship between SUA and markers of TOD such as LVH and microalbuminuria in 842 nondiabetic hypertensive patients, reported that increased SUA levels were associated with microalbuminuria but not with LVH. Viazzi et al, 23 in 425 middle-aged hypertensives, found that the occurrence and severity of TOD progressively increased from the lower to the upper SUA tertile in women but not in men. Finally, Iwashima et al, 26 in 619 treated and untreated aged hypertensive subjects, showed that SUA was independently associated with LVMI, and the combination of hyperuricemia and LVH was a powerful predictor of cardiovascular disease. These conflicting findings are partly related to methodologic differences and to patient characteristics. Experimental and clinical evidence support a pathogenetic role of hyperuricemia in the development of hypertension, cardiovascular alterations, and renal diseases by multiple mechanisms, including endothelial dysfunction, vascular smooth muscle cell proliferation, 27 stimulation of inflammatory responses, 28 and increased platelet adhesiveness. 29 Our data do not exclude that SUA may affect TOD; rather, they indicate that in a population of recently diagnosed mild-to-moderate essential hypertensives with a low prevalence of hyperuricemia, SUA effects on organ involvement are not evident. This observation is noteworthy, as damage in one or two organs was a frequent phenotype in our series. The present findings, however, cannot be generalized to patients with more severe or long-lasting hypertension, older age, and concomitant comorbidities such as diabetes, cardiac, vascular, and renal disease.
In conclusion, our study shows that in a population of mild-to-moderate essential hypertensives at low prevalence of hyperuricemia, the SUA levels do not play a synergistic effect with other risk factors in determining preclinical TOD. It is also suggested that the pathogenetic effect of SUA is dose dependent, the activation of damaging mechanisms occurring at high SUA levels.
